DR. CHONGMING JIANG'S LABORATORY

ABOUT DR. CHONGMING JIANG

Dr. Chongming Jiang is an Assistant Professor at the TIBI. Dr. Jiang received his Ph.D. degree from Sun Yat-sen University and he was a postdoctoral researcher at Weill Cornell Medicine and Baylor College of Medicine, respectively. Dr. Jiang is interested in combining immunomics, AI machine learning, and experimental biology to address unresolved scientific issues in cancer immunotherapy and organ transplantation. Dr. Jiang developed a series of prediction models, AI machine learning frameworks, and databases to investigate the immune infiltration of the microenvironment, improve cancer vaccine and T cell-based cancer immunotherapy, predict new candidate targets, and develop prognostic signatures in cancer and organ transplantation.

CONTACT ME

chongming.jiang@terasaki.org

Google Scholar

LinkedIn

RESEARCH HIGHLIGHTS

RESEARCH OVERVIEW

Dr. Chongming Jiang’s Lab interested in combining immunomics, AI machine learning, and experimental biology to address unresolved scientific issues in cancer immunotherapy and organ transplantation.

Research areas:

(1) Immunomics (Genomics & Immunology)

(2) AI machine learning

(3) Precision Medicine (Cancer, Organ transplantation)

(4) Prognosis and drug response prediction

Immunomics (Genomics & Immunology)

Dr. Jiang’s lab proposes multiple approaches to predict the abundance of a particular class of immune cells and their role in the immune microenvironment based on the genomics data. Dr. Jiang’s lab developed multiple AI machine learning models to investigate the effect of tissue resident memory T cells, tumor associate macrophages, tumor infiltration NK cells, microglia, and B cells in the tumor microenvironment and predict the prognosis of multiple cancer types and the sensitivity of tumor patients to immunotherapy.

1.     Shen A, Garrett A, Chao CC, Liu D, Cheng C, Wang Z, Qian Q, Zhu Y, Mai J, Jiang C†. A Comprehensive Meta-Analysis of Tissue Resident Memory T Cells and Their Roles in Shaping Immune Microenvironment and Patient Prognosis in Non-Small Cell Lung Cancer [J]. Frontiers in Immunology. 2024

2.     Schaafsma E1, Jiang C1, Nguyen T, Zhu K, Cheng C. Microglia-Based Gene Expression Signature Highly Associated with Prognosis in Low-Grade Glioma. Cancers (Basel) (2022) 14: doi:10.3390/cancers14194802

3.     Schaafsma E, Jiang C, Cheng C. B cell infiltration is highly associated with prognosis and an immune-infiltrated tumor microenvironment in neuroblastoma. J Cancer Metastasis Treat (2021) 7:1–17. doi:10.20517/2394-4722.2021.72

AI machine learning

Dr. Jiang’s lab has devised several innovative AI machine learning algorithmic frameworks to evaluate the feasibility of delivering mutant antigen targets into tumor cells. Through these frameworks, we elucidated that T cell-mediated immune surveillance profoundly shapes the mutational landscape of tumors, offering comprehensive biological explanations for observed phenomena. Furthermore, Dr. Jiang’s lab has curated multiple databases encompassing T cell antigenic epitopes and cancer vaccines. Leveraging in-depth analysis and machine learning techniques, these databases facilitate enhanced design of clinical trials for cancer vaccines. Additionally, Dr. Jiang’s lab introduced the AI machine learning algorithms to rapid screening of new antigens at significantly reduced time costs compared to previous methods. Dr. Jiang’s lab contributions extend beyond theoretical advancements, as Dr. Jiang’s lab holds two patents for tumor-specific antigens we identified, with patent publication numbers WO2018058490A1 (China) and US2019224291A1 (USA), respectively.

1.     Jiang C†, Li J, Zhang W, Zhuang Z, Liu G, Hong W, Li B, Zhang X, Chao CC. Potential association factors for developing effective peptide-based cancer vaccines. Front Immunol (2022) 13:1–18. doi:10.3389/fimmu.2022.931612

2.     Jiang C†, Schaafsma E, Hong W, Zhao Y, Zhu K, Chao CC, Cheng C. Influence of T Cell-Mediated Immune Surveillance on Somatic Mutation Occurrences in Melanoma. Front Immunol (2022) 12:1–12. doi:10.3389/fimmu.2021.703821

3.     Kawakita S, Shen A, Chao CC, Wang Z, Cheng S, Li B, Jiang C†. An integrated database of experimentally validated major histocompatibility complex epitopes for antigen-specific cancer therapy. Antib Ther. 2024 Jun 17;7(2):177-186. doi: 10.1093/abt/tbae011.

4.     Chen Z, Zhang B, Guo H, Emani P, Clancy T, Jiang C, Gerstein M, Ning X, Cheng C, Min MR. Binding Peptide Generation for MHC Class I Proteins with Deep Reinforcement Learning. Bioinformatics (2023) 39: doi:10.1093/bioinformatics/btad055

5.     Satoru Kawakita, Aidan Shen, Cheng-Chi Chao, Zhaohui Wang, Siliangyu Cheng, Bingbing Li, Chongming Jiang†. An integrated database of experimentally validated major histocompatibility complex epitopes for antigen-specific cancer therapy [J]. Antibody Therapeutics. 2024.

Precision Medicine(Cancer, Organ transplantation)

Dr. Jiang’s lab research involved identifying key genes and regulatory pathways associated with telomerase changes in progeria patients through multi-omics analysis and experimental validation. Treatment with mTERT lentivirus improved symptoms and prolonged the lifespan of progeria mice. To address the challenges of drug development, Dr. Jiang’s lab utilized patient-derived models for personalized medicine. Using the unique organoid model, MicroOrganoSpheres (MOS). Dr. Jiang’s lab confirmed its reliability in assessing tumor drug response and guiding treatment decisions for colorectal cancer. Dr. Jiang’s lab study highlighted the potential of the MOS model for precision oncology. Dr. Jiang’s lab investigated the regulatory mechanism of the key genes in tumor progression and immune signaling regulation, such as the PHF20 in gliomas and Beclin 2 in inflammation and lymphoma.

Dr. Jiang’s lab combines organ transplantation patients’ clinical data, genomics data, and AI machine learning to predict the immune rejection and long-term outcomes. Dr. Jiang’s lab research contributes to understanding disease mechanisms, identifying therapeutic targets, and improving personalized medicine approaches.

1.     Mojiri A, Walther BK, Jiang C, Matrone G, Holgate R, Xu Q, Morales E, Wang G, Gu J, Wang R, et al. Telomerase therapy reverses vascular senescence and extends lifespan in progeria mice. Eur Heart J (2021) 42:4352–4369. doi:10.1093/eurheartj/ehab547

2.     Ding S, .., Jiang C, et al. Patient-derived micro-organospheres enable clinical precision oncology. Cell Stem Cell (2022) 29:905-917.e6. doi:10.1016/j.stem.2022.04.006

Organ transplantation related:

1. Kawakita, Satoru; Jucaud, Vadim; Wang, Zhaohui; Shen, Xiling; Jiang, Chongming. V-211.2: Computational immuno-profiling and prediction of antibody-mediated rejection in kidney transplant recipients[abstract]. Transplantation. 2024

Prognosis and drug response prediction

Dr. Jiang’s lab integrates the immunomics and AI machine learning to identify genetic characterization and screening of molecular biomarkers to predict prognosis and drug response to therapy in cancer patients.

1.     Aidan Shen, Aliesha Garrett, Cheng-Chi Chao, Dongliang Liu, Chao Cheng, Zhaohui Wang, Chen Qian, Yangzhi Zhu, Junhua Mai, Chongming Jiang†. A Comprehensive Meta-Analysis of Tissue Resident Memory T Cells and Their Roles in Shaping Immune Microenvironment and Patient Prognosis in Non-Small Cell Lung Cancer [J]. Frontiers in Immunology. 2024

2.     Cheng C, Nguyen TT, Tang M, Wang X, Chongming Jiang, Liu Y, Gorlov I, Gorlova O, Iafrate J, Lanuti M, et al. Immune infiltration in tumor and adjacent non-neoplastic regions co-determines patient clinical outcomes in early-stage lung cancer. J Thorac Oncol (2023)100788. doi:10.1016/j.jtho.2023.04.022

Join Our Mission

We aim to combine immunomics, AI machine learning, and biology to investigate the immune infiltration of the microenvironment, improve cancer vaccine and T cell-based cancer immunotherapy, predict new candidate targets, and develop prognostic signatures in cancer and organ transplantation.

Team 

Interns

Alumni

CONTACT US

For more information about our research, to discuss potential collaborations, or to inquire about joining our team, please reach out to us at chongming.jiang@terasaki.org

RESEARCH PAPERS

1. Chongming Jiang†, Cheng-Chi Chao, Jianrong Li, Xin Ge, Aidan Shen, Vadim Jucaud, Chao Cheng†, Xiling Shen†. Tissue-Resident Memory T Cell Signatures from Single-Cell Analysis Associated with Better Melanoma Prognosis [J]. iScience. 2024.

2. Chongming Jiang†,.., Chao Cheng†. Influence of T Cell-Mediated Immune Surveillance on Somatic Mutation Occurrences in Melanoma [J]. Frontiers In Immunology. 2022

3. Chongming Jiang†, et al, Cheng-chi Chao†. Potential association factors for developing effective peptide-based cancer vaccines [J]. Frontiers In Immunology. 2022

4. Chongming Jiang, et al. The tumor diffusion and proliferation on percolation cluster [J]. J Biol Phys. (1.4). 2016.

5. Chongming Jiang, et al. The Anomalous Diffusion of a Tumor Invading with Different Surround in Tissues [J]. PLOS ONE. 2014.

6. Evelien Schaafsma#, Chongming Jiang#, Thinh Nguyen, Kenneth Zhu and Chao Cheng. Microglia-Based Gene Expression Signature Highly Associated with Prognosis in Low-Grade Glioma [J]. Cancers. 2022

7. Kun Xiang , Ergang Wang, .., Chongming Jiang, Yubin Kang, Scott Kopetz, Gregory E. Crawford, Steven M. Lipkin, Xiao-Fan Wang, Hans Clevers, David Hsu, Xiling Shen. Chromatin Remodeling in Patient-Derived Colorectal Cancer Models [J]. Advanced Science. 2024.

8. Renlong Yang, Yuanzhi Shao, Chongming Jiang. Invasiveness of Cancer Populations in a Two-dimensional Percolation cluster: a Stochastic Mathematical Approach [J]. bioRxiv. 2022

9. Evelien Schaafsma, Chongming Jiang, Chao Cheng. B cell infiltration is highly associated with prognosis and an immune-infiltrated tumor microenvironment in neuroblastoma [J]. J Cancer Metastasis Treat. 2021

10. Yanhui Liu, Chongming Jiang, et al. DNA condensation and size effects of DNA condensation agent[J]. Fornt Phys. 2013.

11. Anahita Mojiri, Brand Walter, Chongming Jiang, ..,Kaifu Chen, John P. Cooke. TELOMERASE THERAPY REVERSES VASCULAR SENESCENCE IN HGPS [J]. Canadian Journal of Cardiology.2020

12. Anahita Mojiri, Brandon K Walther, Chongming Jiang, .., John P. Cooke. Telomerase Therapy Reverses Vascular Senescence and Extends Lifespan in Progeria Mice [J]. European Heart Journal. 2021

13. Qianquan Ma, .., Chongming Jiang, .., Rong-Fu Wang. PHF20 Promotes Glioblastoma Cell Malignancies Through a WISP1/BGN-Dependent Pathway [J]. Frontiers in Oncology.2020

14. Motao Zhu, .., Chongming Jiang, .., Kaifu Chen, Rong-Fu Wang. Beclin 2 negatively regulates innate immune signaling and tumor development through non-canonical autophagy[J]. JCI.2020.

15. Yiqin Liang*, Renlong Yang*, Yifan Guo*, Chongming Jiang, .., Yuanzhi Shao. Spatiotemporal dynamics of different growth-diffusion systems on a percolation lattice[J].Physical Review E. 2019.

16. Yanhui Liu, Yingbing Chen, Chongming Jiang, et al. Depletion effect and biomembrane budding [J]. J Biol Phys. 2013.

17. Yanding Zhao, Yadong Dong, Wei Hong, Chongming Jiang, Chao Cheng. Computational modeling of chromatin accessibility identified important epigenomic regulators [J]. BMC Genomics. 2021.

18. Yang, R., Jiang, C. & Shao, Y. Invasiveness of a Growth-Migration System in a Two-dimensional Percolation cluster: A Stochastic Mathematical Approach. Bull Math Biol 84, 104.2022

19. Baoyi Zhang, .., Chongming Jiang, et al, Chao Cheng. Peptide Search with Reinforcement Learning and Mutation Polices for Immunotherapy.[J] Bioinformatics. 2023

20. Shengli Ding, ..,Chongming Jiang, et al. Patient-derived micro-organospheres (MOS) enable clinical precision oncology [J]. Cell Stem Cell. 2022.

21. Chao Cheng*, Thinh Nguyen*, Chongming Jiang, et al. Immune infiltration in tumor and adjacent non-neoplastic regions co-determines patient clinical outcomes in early-stage lung cancer. Journal of Thoracic Oncology. 2023.

22. Satoru Kawakita, Aidan Shen, Cheng-Chi Chao, Zhaohui Wang, Siliangyu Cheng, Bingbing Li, Chongming Jiang†. An integrated database of experimentally validated major histocompatibility complex epitopes for antigen-specific cancer therapy [J]. Antibody Therapeutics. 2024.

23. Aidan Shen, Aliesha Garrett, Cheng-Chi Chao, Dongliang Liu, Chao Cheng, Zhaohui Wang, Chen Qian, Yangzhi Zhu, Junhua Mai, Chongming Jiang†. A Comprehensive Meta-Analysis of Tissue Resident Memory T Cells and Their Roles in Shaping Immune Microenvironment and Patient Prognosis in Non-Small Cell Lung Cancer [J]. Frontiers in Immunology. 2024

ABSTRACTS

1. Chongming Jiang, .., Chao Cheng. Abstract LB528: A microglia associated gene signature predicts survival risk in glioma patients. Cancer Research. 2022

2. Chongming Jiang, .., Bo Li, Chao Cheng. Abstract LB051: The landscape of peptide vaccine in clinical trials for cancer. Cancer Research. 2021

3. Chongming Jiang, Cheng-chi Chao and Chao Cheng. Abstract 6618: A database of potential T cell epitopes for cancer immunotherapy. Cancer Research. 2020

4. Aidan Shen, .., Chongming Jiang†. Abstract 7323: Tissue resident memory T cell abundances impact non-small-cell lung cancer immune microenvironment and patient prognosis. Cancer Research. 2024

5. Youngsoo Han, .., Chongming Jiang†. Abstract 3457: Distinct signatures of tumor-associated macrophage subpopulations predict survival in renal cell carcinoma. Cancer Research. 2024

6. Cheng-chi Chao,..., Chongming Jiang, et al. Abstract LB-202: A novel neoepitope screening platform for generating effective and safe neoantigen-based vaccines and immunotherapeutics in a hepatocellular carcinoma model. Cancer Res. 2017.

7. Anahita Mojiri, Brandon K Walther, Chongming Jiang, .., John P. Cooke. Abstract 11821: Telomerase Therapy Reverses Vascular Senescence and Extends Lifespan in Progeria Mice. Circulation. 2021

8. Chongming Jiang, Jianrong Li, Elena Helman, Xiling Shen, Chao Cheng. Resident memory T cell gene expression signature highly associated with prognosis in melanoma [abstract]. Cancer Res. 2023.

9. Yubin Kang, Xiaobei Wang, Jian Wu, Shaima Jabbar, Chongming Jiang, Xiling Shen, Besim Ogretmen, Inhibition of Sphingosine Kinase 2 Enhances Immunotherapy in Mouse Model of Multiple Myeloma, Blood, Suppl,2023

PATENTS

1. Bo Li, Geng Liu, QIU Si, Dongli Li, Chongming Jiang, et al. US patent publication number is 20190224291 (COL14A1-DERIVED TUMOR ANTIGEN POLYPEPTIDE AND USE THEREOF).

2. Yong Hou, .., Chongming Jiang, Naibo Yang. Chinese patent publication number: WO2018058490A1.